Page 23 - அமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vertex Pays $900M Upfront to Lead CTX001 Development with CRISPR Therapeutics April 20, 2021 Dazzled by early positive results in a pair of Phase I/II trials, Vertex Pharmaceuticals said today it will pay CRISPR Therapeutics $900 million upfront to lead the global development, manufacturing, and commercialization of CTX001, the CRISPR-Cas9 gene-edited therapy co-developed by the companies for a pair of blood disorders, sickle-cell disease (SCD) and beta thalassemia. Under the revised agreement Vertex has agreed to pay 60% of program costs for CTX001 and will receive 60% of profits from future sales of the gene-edited therapy up from the companies’ previous 50-50 split, when Vertex initially agreed to pay $105 million upfront ($75 million cash plus $30 million in equity) for its 50% stake, and CRISPR Therapeutics agreed to lead commercialization of any product developed by the companies.

United statesSamarth kulkarniPhilip gregoryAmerican society of hematologyVertex pharmaceuticalsEuropean commissionBoston globeJeffrey leidenNew england journalAmerican societyஒன்றுபட்டது மாநிலங்களில்சமர்த் குல்கர்னிபிலிப் கிரெகொரிஅமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜிவெர்டெக்ஸ் மருந்துகள்ஐரோப்பிய தரகு